{"id":"ferric-carboxymaltose-fcm","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypophosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":"rare","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FCM is an intravenous iron replacement therapy consisting of ferric iron stabilized in a carbohydrate shell. Once administered, the iron is released and binds to transferrin and ferritin, allowing rapid replenishment of iron stores and hemoglobin synthesis. This mechanism bypasses gastrointestinal absorption limitations and is effective in patients with iron deficiency anemia who cannot tolerate or absorb oral iron.","oneSentence":"Ferric carboxymaltose delivers iron directly into the bloodstream as a stable iron-carbohydrate complex that is taken up by iron-binding proteins to replenish depleted iron stores.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:24.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia in patients with chronic kidney disease (CKD), including those on hemodialysis and non-dialysis dependent patients"},{"name":"Iron deficiency anemia in patients with heart failure"},{"name":"Iron deficiency anemia in non-dialysis dependent CKD patients"}]},"trialDetails":[{"nctId":"NCT07476859","phase":"PHASE4","title":"Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2026-03-05","conditions":"Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)","enrollment":538},{"nctId":"NCT07414199","phase":"PHASE4","title":"The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2026-01-31","conditions":"Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes, Iron Deficiency Anemia Treatment","enrollment":150},{"nctId":"NCT07359599","phase":"PHASE4","title":"The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension","status":"RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-01-27","conditions":"Pulmonary Hypertension, Iron Deficiency","enrollment":306},{"nctId":"NCT07370688","phase":"PHASE4","title":"Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-08-12","conditions":"Aortic Valve Stenosis, Iron Deficiency, TAVI(Transcatheter Aortic Valve Implantation)","enrollment":402},{"nctId":"NCT05309499","phase":"NA","title":"An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function","status":"COMPLETED","sponsor":"Kazan State Medical University","startDate":"2021-12-05","conditions":"Myocardial Infarction, Iron-deficiency","enrollment":298},{"nctId":"NCT06958822","phase":"","title":"Ferric Carboxymaltose Methemoglobinemia Study","status":"COMPLETED","sponsor":"Ordu University","startDate":"2025-04-14","conditions":"Methemoglobinemia, Anemia, Iron-Deficiency, Parenteral Iron Therapy","enrollment":977},{"nctId":"NCT06994065","phase":"NA","title":"Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients","status":"RECRUITING","sponsor":"Sindh Institute of Urology and Transplantation","startDate":"2025-06-02","conditions":"Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","enrollment":128},{"nctId":"NCT05759078","phase":"PHASE4","title":"Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2022-09-22","conditions":"Myocardial Infarction, Acute","enrollment":1000},{"nctId":"NCT07053475","phase":"PHASE4","title":"IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches","status":"RECRUITING","sponsor":"Syed Hamza Mufarrih","startDate":"2025-04-02","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":250},{"nctId":"NCT01950247","phase":"PHASE4","title":"Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2013-08-15","conditions":"Iron Deficiency Anemia (IDA)","enrollment":1025},{"nctId":"NCT06895993","phase":"PHASE1","title":"Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-04-07","conditions":"Healthy Adult","enrollment":84},{"nctId":"NCT00685815","phase":"PHASE2","title":"Intravenous Iron Metabolism in Restless Legs Syndrome","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2006-11","conditions":"Restless Legs","enrollment":12},{"nctId":"NCT06948864","phase":"","title":"Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia","status":"COMPLETED","sponsor":"Hospital Universitario Infanta Cristina","startDate":"2020-01-01","conditions":"Anemia, Anemia (Iron-Loading), Perioperative Bleeding","enrollment":152},{"nctId":"NCT05816265","phase":"PHASE4","title":"Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Radha Gopalan","startDate":"2024-01-24","conditions":"Heart Failure, Iron-deficiency","enrollment":40},{"nctId":"NCT02826681","phase":"PHASE2","title":"Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia","status":"TERMINATED","sponsor":"American Regent, Inc.","startDate":"2017-07-10","conditions":"Restless Legs Syndrome (RLS)","enrollment":70},{"nctId":"NCT06080893","phase":"PHASE4","title":"The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2023-10-10","conditions":"Hip Fractures, Anemia, Complication,Postoperative","enrollment":209},{"nctId":"NCT03036462","phase":"PHASE4","title":"Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-03-07","conditions":"Systolic Heart Failure, Iron Deficiency","enrollment":1105},{"nctId":"NCT03037931","phase":"PHASE3","title":"Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2017-03-15","conditions":"Heart Failure, Iron-deficiency","enrollment":3065},{"nctId":"NCT03074591","phase":"PHASE4","title":"Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2017-08-01","conditions":"Iron-deficiency, Heart Failure","enrollment":40},{"nctId":"NCT06080555","phase":"PHASE1","title":"Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2023-10-09","conditions":"Iron Deficiency, Anaemia","enrollment":84},{"nctId":"NCT05226169","phase":"PHASE3","title":"Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2022-04-29","conditions":"Advanced Gastric Carcinoma","enrollment":330},{"nctId":"NCT05702970","phase":"PHASE4","title":"Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2024-01-15","conditions":"Heart Failure, Iron-deficiency, Heart Failure, Systolic","enrollment":258},{"nctId":"NCT02694978","phase":"PHASE3","title":"A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2016-02-29","conditions":"Iron Deficiency Anemia","enrollment":2014},{"nctId":"NCT04976179","phase":"PHASE3","title":"Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON)","status":"COMPLETED","sponsor":"University of Lagos, Nigeria","startDate":"2021-08-09","conditions":"Iron Deficiency Anemia of Pregnancy","enrollment":1056},{"nctId":"NCT04968379","phase":"PHASE2","title":"Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia","status":"WITHDRAWN","sponsor":"American Regent, Inc.","startDate":"2022-07-21","conditions":"Iron Deficiency, Anaemia","enrollment":""},{"nctId":"NCT04083755","phase":"PHASE4","title":"Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)","status":"UNKNOWN","sponsor":"Biobizkaia Health Research Institute","startDate":"2019-08-15","conditions":"Anemia, Peripheral Arterial Occlusive Disease","enrollment":240},{"nctId":"NCT04141631","phase":"NA","title":"Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2020-01-13","conditions":"Cardiac Surgery, Transfusion, Perioperative Anemia","enrollment":128},{"nctId":"NCT05505006","phase":"PHASE4","title":"Management of Preoperative Anaemia in Surgical Oncology","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-03-02","conditions":"Anemia, Tumor","enrollment":500},{"nctId":"NCT05477498","phase":"PHASE4","title":"Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction","status":"WITHDRAWN","sponsor":"Cantonal Hosptal, Baselland","startDate":"2021-12-01","conditions":"Heart Failure With Normal Ejection Fraction, Iron-deficiency","enrollment":""},{"nctId":"NCT02410213","phase":"PHASE2","title":"A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-02-19","conditions":"Iron Deficiency Anemia (IDA)","enrollment":35},{"nctId":"NCT03523117","phase":"PHASE3","title":"Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2019-01-31","conditions":"Iron Deficiency Anemia","enrollment":79},{"nctId":"NCT01100879","phase":"PHASE4","title":"Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy","status":"TERMINATED","sponsor":"Vifor Pharma","startDate":"2010-03","conditions":"Iron-Deficiency Anemia","enrollment":3},{"nctId":"NCT04269707","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2019-11-19","conditions":"Iron Deficiency Anemia","enrollment":7},{"nctId":"NCT04246021","phase":"NA","title":"Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy","status":"COMPLETED","sponsor":"King Hussein Cancer Center","startDate":"2016-06-15","conditions":"Anemia, Cancer","enrollment":84},{"nctId":"NCT04974021","phase":"","title":"Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-06-20","conditions":"Ferric Carboxymaltose, Heart Failure With Reduced Ejection Fraction, Arrhythmias, Cardiac","enrollment":106},{"nctId":"NCT02937454","phase":"PHASE4","title":"Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency","status":"COMPLETED","sponsor":"Vifor (International) Inc.","startDate":"2017-04-03","conditions":"Iron Deficiency, Heart Failure","enrollment":1132},{"nctId":"NCT03591406","phase":"PHASE3","title":"To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia","status":"COMPLETED","sponsor":"Vifor (International) Inc.","startDate":"2017-07-03","conditions":"Iron Deficiency Anemia","enrollment":371},{"nctId":"NCT04898569","phase":"PHASE4","title":"Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-02-10","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT02453334","phase":"PHASE3","title":"Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-05-23","conditions":"Cancer and Chemotherapy Related Anemia","enrollment":244},{"nctId":"NCT04627181","phase":"PHASE4","title":"Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?","status":"UNKNOWN","sponsor":"Christian Medical College, Vellore, India","startDate":"2020-11-18","conditions":"Iron Deficiency Anemia, B12 Deficiency Anemia","enrollment":100},{"nctId":"NCT02905539","phase":"PHASE4","title":"A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2016-07","conditions":"Anemia, Iron-Deficiency","enrollment":26},{"nctId":"NCT02086968","phase":"PHASE4","title":"Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2014-01-01","conditions":"Iron Deficiency Anemia Secondary to IBD or Gastric Bypass","enrollment":198},{"nctId":"NCT04510870","phase":"PHASE4","title":"Iron Deficiency as an Ignored Cause of Infertility","status":"UNKNOWN","sponsor":"Dextra Fertility Clinic","startDate":"2020-08-17","conditions":"Iron Deficiency, Infertility","enrollment":62},{"nctId":"NCT02949947","phase":"PHASE2","title":"Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-18","conditions":"Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation","enrollment":3},{"nctId":"NCT03191201","phase":"PHASE4","title":"A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.","status":"TERMINATED","sponsor":"Prof Gérard WAEBER","startDate":"2017-06-21","conditions":"Iron-deficiency, Iron Toxicity, Glucose Metabolism Disorders (Including Diabetes Mellitus)","enrollment":32},{"nctId":"NCT03398681","phase":"PHASE4","title":"Changes in Myocardial Iron After Iron Administration","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2017-05-01","conditions":"Heart Failure, Iron-deficiency","enrollment":53},{"nctId":"NCT00982007","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2009-09","conditions":"Iron Deficiency Anemia","enrollment":997},{"nctId":"NCT00317226","phase":"PHASE3","title":"Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2005-06","conditions":"Anemia","enrollment":145},{"nctId":"NCT00704353","phase":"PHASE3","title":"Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2008-06","conditions":"Anemia","enrollment":735},{"nctId":"NCT00548691","phase":"PHASE3","title":"Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2007-10","conditions":"Anemia","enrollment":513},{"nctId":"NCT00703937","phase":"PHASE3","title":"Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2008-07","conditions":"Anemia","enrollment":708},{"nctId":"NCT00548860","phase":"PHASE3","title":"Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2007-10","conditions":"Anemia","enrollment":2018},{"nctId":"NCT00354484","phase":"PHASE3","title":"Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2006-05","conditions":"Postpartum Anemia","enrollment":291},{"nctId":"NCT00395993","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2005-05","conditions":"Anemia","enrollment":456},{"nctId":"NCT00317239","phase":"PHASE3","title":"VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2005-05","conditions":"Anemia","enrollment":255},{"nctId":"NCT00704028","phase":"PHASE3","title":"Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2008-06","conditions":"Anemia","enrollment":161},{"nctId":"NCT01382901","phase":"PHASE2","title":"Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2006-03","conditions":"Restless Legs Syndrome (RLS)","enrollment":45},{"nctId":"NCT02409459","phase":"PHASE2","title":"Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2015-03","conditions":"Iron Deficiency, Fibromyalgia","enrollment":81},{"nctId":"NCT00981045","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2009-08","conditions":"Iron Deficiency Anemia, Impaired Renal Function","enrollment":2561},{"nctId":"NCT01307007","phase":"PHASE2","title":"Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2010-09","conditions":"Iron Deficiency Anemia","enrollment":69},{"nctId":"NCT01290315","phase":"PHASE2","title":"Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2009-08","conditions":"Iron Deficiency Anemia","enrollment":49},{"nctId":"NCT01984554","phase":"","title":"Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2013-09","conditions":"Iron Deficiency Anemia (IDA)","enrollment":551},{"nctId":"NCT03050424","phase":"PHASE2","title":"Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2017-04-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":40},{"nctId":"NCT01131624","phase":"PHASE3","title":"Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2010-05","conditions":"Anaemia","enrollment":252},{"nctId":"NCT02232906","phase":"PHASE4","title":"Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Hospital Aleman","startDate":"2011-03","conditions":"Iron Deficiency, Anaemia","enrollment":30},{"nctId":"NCT00994318","phase":"PHASE3","title":"Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2009-12","conditions":"Iron Deficiency Anaemia, Chronic Kidney Disease","enrollment":626},{"nctId":"NCT01101399","phase":"PHASE3","title":"Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2010-05","conditions":"Iron-Deficiency Anemia","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":405,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Injectafer","infusion","VIT-45","Ferinject","injectafer"],"phase":"marketed","status":"active","brandName":"Ferric Carboxymaltose (FCM)","genericName":"Ferric Carboxymaltose (FCM)","companyName":"American Regent, Inc.","companyId":"american-regent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ferric carboxymaltose delivers iron directly into the bloodstream as a stable iron-carbohydrate complex that is taken up by iron-binding proteins to replenish depleted iron stores. Used for Iron deficiency anemia in patients with chronic kidney disease (CKD), including those on hemodialysis and non-dialysis dependent patients, Iron deficiency anemia in patients with heart failure, Iron deficiency anemia in non-dialysis dependent CKD patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}